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1. Introduction
High-density lipoproteins (HDL) consist of various subclasses,
which share the abundance of apolipoprotein (apo) A-I, phos-
pholipids, and cholesterol but are distinct by the variable
presence of one or more representatives of at least 85 proteins
and hundreds of lipid species [1,2]. HDL are circulating multi-
molecular platforms that exert divergent functions: reverse
cholesterol transport, anti-inflammatory effects, antioxidative
properties, immunomodulatory effects, improvement of
endothelial function, antithrombotic effects, and potentiation
of insulin secretion and improvement of insulin sensitivity [2].
Plasma HDL-cholesterol levels and plasma levels of its
major apo, apo A-I, are inversely correlated with the incidence
of ischemic cardiac diseases. A meta-analysis of four prospec-
tive studies indicated that a 1 mg/dL increase in HDL-
cholesterol was associated with a 2% risk reduction of coron-
ary heart disease in men and a 3% risk reduction in women [3].
In a more recent analysis of The Emerging Risk Factors
Collaboration, the adjusted hazard ratio for coronary heart
disease associated with a one standard deviation increase of
HDL-cholesterol (15 mg/dL) was 0.78 (95% confidence interval,
0.74–0.82) [4]. In contrast, Mendelian randomization studies
have demonstrated that genetic mechanisms that raise
plasma HDL-cholesterol do not appear to lower the risk of
myocardial infarction [5]. The possibility that the epidemiolo-
gical relationship between HDL-cholesterol and coronary
artery disease in classical epidemiological studies reflects resi-
dual confounding and/or unmeasured confounding cannot be
excluded. Low HDL-cholesterol could be an integrated bio-
marker of adverse metabolic processes including abnormal
metabolism of triglyceride-rich lipoproteins, insulin resistance,
and ongoing tissue inflammation [2].
Based on the biological potential of HDL and on epidemio-
logical evidence, the development of HDL-targeted therapies
has been an important objective for several decades. According
to the original HDL hypothesis, raising HDL-cholesterol was
expected to lead to a decrease in coronary heart disease risk.
However, HDL-cholesterol is a very poor proxy to analyze bio-
logical action and clinical effects of HDL. Scavenger receptor
class B type I is the major receptor for HDL-cholesterol, and a
rare variant abrogates selective HDL-cholesterol uptake, raises
HDL-cholesterol, and increases the risk of coronary heart dis-
ease [6]. In general, genetic or pharmacological modifications of
HDL metabolism and associated compositional changes of the
proteome or lipidome of HDL particles may lead to an impaired
function of these lipoproteins. Reduced HDL function may also
be due to post-translational modifications of proteins or occur
as a result of ongoing inflammation [7]. HDL function encom-
passes several dimensions: cholesterol efflux capacity, vasculo-
protective function, anti-inflammatory potential, and
antioxidative capacity. Rohatgi et al. [8] demonstrated in a
seminal prospective cohort study that HDL-cholesterol efflux
capacity predicted incident cardiovascular events independent
of traditional risk factors, HDL-cholesterol level, and HDL-
particle concentration. According to a modified version of the
HDL hypothesis, improving HDL function will lead to a decrease
of coronary events [2].
2. Biological HDL-targeted therapies
The HDL hypothesis remains unproven till now. The stringent
requirement for proving or refuting this hypothesis is HDL
specificity of the intervention, which implies that the causal
pathway between the therapeutic intervention and a hard
clinical endpoint obligatory passes through HDL. None of the
HDL-raising small chemical compounds that have been eval-
uated till now in randomized phase III trials (niacin, fibrates,
torcetrapib, dalcetrapib, evacetrapib) is characterized by HDL
specificity. It should be noted that all these drugs were eval-
uated on a background of the best available therapy including
statins. In contrast, infusion therapy of reconstituted HDL
particles [9] and human apo A-I gene transfer [2] are biological
HDL-targeted therapies that are distinguished by HDL specifi-
city. Apo A-I is the major protein component of HDL and plays
a critical role in the biological properties of HDL. Reconstituted
HDL contain recombinant or purified apo A-I in combination
with phospholipids and are a source of lipid-poor pre–β-HDL-
like particles that interact efficiently with ATP-binding cassette
transporter A1 [2]. The effect of reconstituted HDL on bio-
chemical endpoints, on HDL function, on coronary intravascu-
lar ultrasound parameters, and on safety endpoints including
hepatotoxicity and renal toxicity has been evaluated in several
clinical trials [10,11]. An exhaustive discussion of different
coronary intravascular ultrasound trials investigating the
effects of biological HDL-targeted therapies is outside the
scope of this manuscript. In general, whereas positive effects
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of reconstituted HDL therapy on HDL function have been
observed, no single reconstituted HDL infusion therapy study
has demonstrated clear regression of atherosclerosis. These
observations are entirely consistent with experimental data
showing that human apo A-I overexpression in mice also fails
to induce regression of advanced atherosclerotic lesions
[12,13]. Whether regression of atherosclerosis is an acceptable
imaging biomarker will be discussed later.
Infusion of lipid-poor pre-β-HDL-like particles in patients
with coronary heart disease may induce cholesterol unloading
in lesions and/or reduce plaque inflammation and vulnerabil-
ity. On the other hand, the enzyme lecithin:cholesterol acyl-
transferase (LCAT) might be rate limiting in patients with
coronary heart disease, which often have elevated levels of
pre-β-HDL and low levels of large, cholesteryl ester-rich HDL
(α1-HDL) [14]. LCAT catalyzes the production of cholesteryl
ester from free cholesterol and phosphatidylcholine. This reac-
tion predominantly occurs on HDL (α-LCAT activity) and to a
lesser extent on apo B-containing particles (β-LCAT activity).
LCAT plays an essential role in HDL remodeling by promoting
the maturation of small discoidal forms of HDL (pre-β-HDL and
α4-HDL) into larger spherical forms of HDL (α1-3-HDL) [14]. A
phase 1b, open-label, single-dose escalation study was con-
ducted to evaluate safety, tolerability, pharmacokinetics, and
pharmacodynamics of recombinant human LCAT (ACP-501;
AstraZeneca) in subjects with stable coronary heart disease
and low HDL-cholesterol [14]. HDL-cholesterol 6 h after the
two highest doses of 9.0 and 13.5 mg/kg was increased by
36% and 42%, respectively, and remained above baseline for
4 days. ACP-501 potentiated ex vivo cholesterol efflux.
3. Surrogate endpoints versus clinically meaningful
endpoints
The future of biological HDL-targeted therapies in patients
with stable coronary heart disease or with acute coronary
syndromes is closely linked to the demonstration of an effect
on clinically meaningful primary endpoints (clinical efficacy
measures). A surrogate endpoint is an outcome measure
used as a substitute for a clinically meaningful endpoint
whereby changes induced by a therapy on a surrogate end-
point are expected to reflect changes in a clinically meaningful
endpoint. The surrogacy of specific biomarkers in current
clinical trials evaluating biological HDL-targeted therapies is
a critical issue that should be addressed. With regard to cor-
onary intravascular ultrasound studies evaluating imaging bio-
markers, the inherent assumption is that changes in plaque
volume are on the causal pathway between intervention and
clinical efficacy measure, for example, coronary events. A
direct relationship between atheroma progression and regres-
sion on coronary intravascular ultrasound and hard clinical
events has never been clearly demonstrated [15]. It is perfectly
possible that a greater clinical effect is produced by altering
plaque composition from lipid-rich to more fibrotic tissue, thus
stabilizing the plaque, independent of any change in lumen
area or plaque volume. Whereas an unequivocal and clinically
important effect of the proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibitor evolocumab on top of statins has
been recently demonstrated in the FOURIER trial for the pri-
mary and key secondary endpoint, the effect of this drug
on percent atheroma value in the GLAGOV trial was, although
clearly statistically significant, limited [16]. There is a risk of
false-negative conclusions about clinical efficacy if the biomar-
ker does not lie in the disease process causal pathway that is
meaningfully impacted by the intervention. This might be the
case with coronary intravascular ultrasound parameters of
plaque volume. Consequently, one of the obvious concerns
is that coronary intravascular ultrasound studies evaluating
biological HDL-targeted therapies, which fail to reach the
primary endpoint, may lead to the erroneous conclusion that
no effect on hard clinical endpoints can be expected. The
problems surrounding potential surrogate imaging endpoints
are also exemplified by data on carotid intima-media thick-
ness. Although carotid intima-media thickness is associated
with future cardiovascular disease event risk, regression or
slowed progression of carotid intima-media thickness, induced
by cardiovascular drug therapies, does not reflect a reduction
in cardiovascular events [17]. In general, a strong correlation
between a biomarker and a clinical endpoint in natural history
observations does not necessarily imply that the biomarker is
a (non-validated) surrogate that reasonably likely predicts clin-
ical benefit. Moreover, biomarkers that are strongly correlated
with clinical efficacy measures in natural history observations,
yet are not in the causal pathway of the disease process, as is
the case for carotid intima-media thickness, are likely to pro-
vide misleading information about clinical efficacy.
The primary outcome measure in definitive trials should
be a clinical event relevant to the patient or an endpoint that
measures directly how a patient feels, functions, or survives,
where function refers to patients’ ability to perform activities
in their daily lives [18]. In a less ideal situation, an endpoint
can be a validated surrogate for a clinically meaningful end-
point. The central point is that there are no validated surro-
gate endpoints available for biological HDL-targeted
therapies. This is clear from a logical point of view since no
trials with a clinically meaningful primary endpoint have
been conducted till now and thus, validation has never
been performed. In contrast, in the setting of hypolipidemic
therapies, low-density lipoprotein (LDL) cholesterol is a rea-
sonable surrogate endpoint because based on prior art, a
strong linear relationship has been demonstrated between
absolute LDL-cholesterol reduction (mmol/L) and reduction
of the rate of major cardiovascular events (%). However, even
a validated surrogate endpoint constitutes an imperfect sub-
stitute of a clinically meaningful endpoint since such end-
point unlikely captures the complete effect of the
intervention. Specifically, the intervention may modify causal
pathways that have an impact on the endpoint but are
unrelated to the biomarker that serves as a surrogate end-
point. If we assume that parameters of HDL functionality are
on the causal pathway of atherosclerotic vascular disease,
false-positive conclusions about clinical efficacy may arise if
HDL function captures substantial effects of an intervention
on one causal pathway of the disease process, while the
intervention has an inadequate impact on other principal
causal pathways.
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4. Conclusion
The current state of the art on the effects of HDL-targeted
therapies is faced with a lack of a validated surrogate endpoint
and suffers from uncertainty with regard to non-validated
surrogates that reasonably likely predict clinical outcomes.
This may lead to false-negative and false-positive conclusions.
A statistical power calculation for a trial with a clinically
meaningful primary endpoint is critically dependent on the
assumption with regard to the expected hazard ratio. The
required number of events is inversely proportional to (log
(hazard ratio))2. The required number of events is, for example,
2.38-fold higher for a hazard ratio of 0.9 compared to a hazard
ratio of 0.85 for the same level of statistical significance and
statistical power. In the absence of any prior art, it is very hard
to predict the hazard ratio.
Taken together, in light of all these considerations, it is far
from evident to prove or to refute the HDL hypothesis in the
setting of atherosclerotic vascular disease.
5. Expert opinion
One approach is to restrict biological HDL-targeted therapies
to patients with familial primary hypoalphalipoproteinemia,
which concerns a relatively low number of patients. In these
subjects, a biochemical endpoint is acceptable since the
objective of the intervention is to treat a protein deficiency.
Lack of detectable plasma apo A-I can be due to DNA dele-
tions, rearrangements, or nonsense or frameshift mutations
within the APOA1 gene and results in premature coronary
heart disease [19]. This disorder is a clear target for adeno-
associated viral serotype 8 (AAV8)-mediated human apo A-I
gene therapy. Familial LCAT deficiency is characterized by
extremely low HDL-cholesterol, corneal opacities, anemia,
and progressive renal disease but no marked increase of
coronary heart disease [19]. This disorder may be treated
with recombinant LCAT protein therapy.
Another option is to consider new therapeutic areas for
HDL-targeted interventions [2]. Pleiotropic effects of HDL
might be translated in clinically significant effects in strategi-
cally selected therapeutic areas that are not directly related to
native coronary artery disease. In particular, HDL-targeted
therapies might be useful in the setting of critical illness [2]
via its anti-inflammatory and antioxidative effects and in the
setting of heart failure (HF). HF is a growing public health
problem, the leading cause of hospitalization, and a major
cause of mortality. Approximately 50% of chronic HF patients
have HF with reduced ejection fraction (HFrEF) and 50% suffer
from HF with preserved ejection fraction (HFpEF). As the
population ages, HFpEF will continue to be a growing public
health problem. In contrast to advances in the treatment of
patients with HFrEF, drug strategies with strong evidence in
HFrEF have proved unsuccessful in HFpEF and the mortality in
patients with HFpEF has remained unchanged. The rationale
for HDL-targeted therapies in this setting is based on biologi-
cal, epidemiological, and experimental evidence [20].
Specifically, HDL-targeted therapies improve diastolic function
and exert antifibrotic effects [20].
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